Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5624983 | Alzheimer's & Dementia | 2012 | 8 Pages |
Abstract
A low percentage of individuals with AD in the community are taking cholinesterase inhibitors or memantine. This study suggests that women, particularly those with an APOE É4 allele, may benefit the most from these medications. With the newly approved increased dose of donepezil, it will be imperative to determine whether a higher dose is needed in men or whether other factors warrant consideration.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Michelle M. Mielke, Jeannie-Marie Leoutsakos, Chris D. Corcoran, Robert C. Green, Maria C. Norton, Kathleen A. Welsh-Bohmer, JoAnn T. Tschanz, Constantine G. Lyketsos,